With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
CTVA — frequently asked questions
Is Corteva Inc. overvalued?
In our latest published analysis dated 2026-10-03, CTVA looks meaningfully undervalued. The price recorded at analysis is USD 11.9 versus our fair value of USD 51.7; the high endpoint is presented separately as potential value of USD 73.7. That implies roughly 334.0% upside to fair value at that date.
Our latest published report, analyzed 2026-10-03, gives CTVA a fair value of USD 51.7 and a potential value of USD 73.7. The conclusion is triangulated across multiple valuation models and weighted by reliability for Corteva Inc.'s archetype; it is a dated research output, not a live price.
Should I buy CTVA now?
Our latest published rating for CTVA, analyzed 2026-10-03, is Strong Buy. Corteva Inc. looks meaningfully undervalued at the analysis-date price of USD 11.9 versus fair value of USD 51.7; potential value is USD 73.7. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for CTVA?
The dedicated bear-case section in our report analyzed 2026-10-03 documents Corteva Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is CTVA's rating?
Our latest published rating for CTVA, analyzed 2026-10-03, is Strong Buy, with a published moat assessment of 7.2/10 (Narrow). It reflects our fair value of USD 51.7, the potential value of USD 73.7, and the price recorded at analysis (USD 11.9).
The biggest opportunity lies in accelerated global adoption of Corteva's proprietary seed trait licensing platform, which is currently running three years ahead of management's original schedule.
Main risk
Consolidated operating margin compressing below 12.0% of revenue driven by mid-single-digit price declines in Crop Protection and persistent generic chemical pricing deflation.
Corteva Inc. (CTVA) is rated Strong Buy with an intrinsic fair value of $51.73 USD, offering an implied upside of 333.98% against the October 2, 2026 share price of $11.92 USD. The market is mispricing Corteva as an undifferentiated commodity chemical producer, failing to reflect its high-margin seed trait licensing platform tracking three years ahead of plan, a renewed crop protection portfolio reaching $2.0B in patented molecule sales, and a robust balance sheet carrying $1.95B in net cash.4,5
At the October 2, 2026 share price of $11.92 USD, Corteva trades at an extreme 76.96% discount to our intrinsic fair value of $51.73 USD, establishing an implied upside of 333.98%. Our valuation is anchored on a multi-year cash flow model capturing normalized operating margin expansion from 15.2% in FY2026 toward 16.2% by FY2030 discounted at an authenticated 6.49% WACC, alongside a forward earnings model capitalizing consensus forward earnings at a justified terminal P/E of 15.5x. The market's valuation implicitly prices in multi-year earnings contraction, overlooking Corteva's durable pricing power and expanding proprietary trait royalty streams.2,4
Corteva's operational foundation rests on two synergistic divisions generating $17,401M in FY2025 consolidated revenue. The Seed segment ($9,898M FY2025 revenue, or 56.88% of consolidated sales) benefits from proprietary Pioneer germplasm and the Enlist trait platform, where out-licensing royalties are tracking literally three years ahead of management's original schedule. Concurrently, Crop Protection ($7,503M FY2025 revenue, or 43.12% of sales) is actively renewing its chemistry portfolio. Patented new molecules and biologicals will touch $2.0B in revenue during FY2026, supported by a pipeline of seven new active ingredients over the next decade. This shift insulates Corteva from the generic active ingredient deflation that has severely impaired commodity peers.5,6,7
Geographic diversification provides substantial counter-cyclical stabilization. In FY2025, Latin America generated $3,928M (22.57% of total sales), led by Brazil at $2,900M (16.67% of sales), complementing the United States core ($8,269M, or 47.52% of sales). Southern Hemisphere planting cycles allow Corteva to rotate working capital and sustain manufacturing asset utilization year-round. While tight Brazilian grower credit and flat safrinha corn planted area create near-term friction, Corteva's advance order books lead the industry, underpinning our projected consolidated revenue expansion toward $18,116M in FY2026.5,7
Corteva maintains exceptional balance sheet durability, supported by $1,950M in net cash and $3,406M in FY2025 operating cash flow. Capital expenditures of $591M in FY2025 yield robust free cash flow, comfortably funding continuous R&D reinvestment alongside aggressive share repurchases of $1,071M in FY2025. With annual repurchases significantly outpacing stock-based compensation of $54M, diluted share count is projected to contract at a 1.0% annual rate. This disciplined capital allocation cushions cyclical downturns and enhances long-term compounding per share.4,6
Massive Valuation Disconnect with Asymmetric Upside
Corteva's share price of $11.92 USD as of October 2, 2026 trades at a 76.96% discount to our intrinsic fair value of $51.73 USD. The market prices CTVA at an implied 10-year earnings contraction rate of -9.66%, offering an exceptional margin of safety for a business with 15.2% operating margins and a 6.49% WACC.2,4
Seed Trait Out-Licensing Running Three Years Ahead of Schedule
Management confirmed in Q2 2026 that high-margin seed trait licensing is tracking literally three years ahead of its original multi-year plan. The $9,898M Seed division generates recurring, high-margin royalty streams from third-party breeders that widen gross margins and enhance cash flow predictability.
House recommendation
Corteva offers an exceptional risk-adjusted total return profile supported by high-margin proprietary seed biotechnology, disciplined capital allocation, and resilient free cash flow. With shares trading at $11.92 USD —a 76.96% discount to our intrinsic fair value of $51.73 USD —the market heavily discounts near-term agrochemical price softness while ignoring multi-year royalty compounding and structural balance sheet strength. We recommend an aggressive accumulation stance for long-horizon investors.4
Company overview
The key raw materials for the Seed segment include corn and soybean seeds. To produce high-quality seeds, the company contracts with third-party growers globally. Corteva focuses on production close to the customer to provide the seed product, which is suitable for that region and its weed, insect and disease challenges, weather, soil and other conditions. Substantially all of Corteva's revenue is derived from product sales, which consist of sales of Corteva's products to farmers, distributors, and manufacturers. Corteva considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer.
Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year.
In a sustained cyclical stress environment, global grain price deflation across corn and soybean futures impairs farmer profitability, triggering down-trading to lower-trait seed hybrids and deferred crop protection chemical applications. Channel destocking intensifies, pulling operating margins toward the FY2023 downcycle trough of 5.46% ($941M operating income on $17,226M revenue), mirroring severe distress observed at peers like FMC (-17.5% revenue decline and net loss margin of -84.83%). In Latin America, credit tightening and halted safrinha planted area exacerbate foreign exchange drag, compressing diluted EPS toward the consensus low of $2.50 in FY2027. Under this stress scenario, intrinsic valuation falls to $35.53, anchoring the low end of the committee's fair value range.
Corteva's narrow economic moat is anchored by proprietary seed genetics and advanced biotechnology traits within its flagship Seed segment ($9,898M FY2025 revenue, or 56.88% of consolidated sales). The company's Pioneer germplasm library and proprietary Enlist weed control system create powerful commercial switching costs, as growers rely on proven local yield performance and trait packages. Out-licensing of Enlist traits to competing seed companies is tracking three years ahead of management's original multi-year schedule, converting potential competitors into recurring royalty contributors and eliminating historic trait fee outflows.
In Crop Protection ($7,503M FY2025 revenue), Corteva defends margins against generic chemical price competition by shifting its portfolio toward newly patented active molecules and biological formulations. New product portfolio sales are touching $2.0B in FY2026 with premium pricing power, and seven new active ingredients are scheduled for commercial launch over the next decade. This systematic chemical renewal isolates Corteva from the severe margin destruction experienced by undifferentiated chemical peers such as FMC (-17.5% revenue contraction and -84.83% net margin).
The highlighted cell is Fair value when every assumption sits at its base level ($51.73). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $1.6B after modeled reinvestment of $353.6M, with terminal value at 82.5% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Seed trait out-licensing royalties exceeding multi-year milestones and accelerated new crop protection sales confirm thesis acceleration, preserving maximum conviction without requiring rating adjustment.
In-line
Maintain Strong Buy; Maintain existing target allocation, monitoring Brazil credit collection terms and safrinha planting indications into the subsequent quarter.
Results consistent with baseline expectations confirm that cost productivity and new product introductions are successfully offsetting generic chemical pricing deflation.
Crop protection pricing declined low single digits in 1H 2026 with mid-single-digit declines expected in 2H 2026. Agricultural chemical peers exhibit severe cyclical distress: FMC suffered a revenue contraction of -17.5% and net margin of -84.83%, while Mosaic recorded -6.0% revenue contraction and -0.12% operating margin. As industry-wide capex/revenue and capacity lead-time benchmarks are unavailable in the evidence packet, this capital cycle assessment is demand-led and evidence-limited.5
Bull cycle
A sharp cyclical recovery driven by rising corn and soybean futures, expanding farm income, aggressive safrinha planting expansion in Brazil, and rapid adoption of premium biologicals and Enlist seed traits, expanding operating margins toward 17.5%.
§11 Position management
Sizing
5-7%
High conviction is warranted by the 76.96% market price discount to our $51.73 fair value midpoint, backed by $1.95B net cash on the balance sheet, resilient seed trait out-licensing tracking three years ahead of plan, and proven $2.8B+ annual free cash flow generation.5
Risk
Position risk is governed by strict allocation caps (maximum 5-7% of equity portfolio), portfolio-level exposure limits to agricultural commodity cycles, and ongoing monitoring of South American credit terms. The company's balance sheet with $1.95B in net cash and multi-year positive free cash flow ($2,815M in FY2025) provide robust organic downside insulation against cyclical macro shocks.
§12 Investor perspectives
Long-Horizon Fundamental Investor
Buy
Corteva provides rare exposure to global agricultural demand backed by proprietary seed biotechnology and a narrow economic moat (Score 7.2). Trading at $11.92 USD as of October 2, 2026 against a fair value of $51.73 USD, investors capture a 76.96% price discount and an underleveraged balance sheet with $1.95B net cash and $3,406M in operating cash flow.4
Valuation & Total Return Investor
Buy
At $11.92 USD, the market implies an unrealistic 10-year earnings contraction of -9.66%. Our forward earnings model ($40.54 midpoint) and discounted cash flow model ($64.73 midpoint) at a 6.49% WACC indicate 333.98% upside potential, further augmented by annual share repurchases exceeding $1.0B.
§14 Final recommendation
Action
Strong Buy
We recommend a Strong Buy on Corteva Inc. (CTVA) with an intrinsic fair value target of $51.73 USD, offering 333.98% implied upside from the October 2, 2026 share price of $11.92 USD. The company's competitive positioning in proprietary seed biotechnology, coupled with new patented crop protection chemistry reaching $2.0B in FY2026, creates a highly resilient earnings platform that the market has fundamentally mispriced as a cyclical commodity chemical producer.4,5
Investors should capitalize on current cyclical weakness to establish full positions. Corteva's balance sheet ($1.95B net cash) and robust operating cash flow ($3,406M in FY2025) provide complete solvency insulation against near-term Latin American credit tight spots, while accelerating seed out-licensing royalties running three years ahead of plan will drive multi-year multiple re-rating toward historical norms.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-03 · Published 2026-10-03 · Provider-adjusted · cited for 2 figuresCited in Bear case, Scenarios
Patented Chemistry Renewal Defends Against Generic Deflation
While generic agrochemical competitors suffer margin collapse and negative net earnings, Corteva's differentiated crop protection portfolio is expanding. New proprietary molecules and biologicals will reach $2.0B in FY2026 revenue, supported by seven new active molecules over the next decade.5
Severe agricultural crop price deflation prompts farmer resistance to premium seed traits
Agrochemical channel destocking resumes, pushing operating margins toward the FY2023 cyclical trough of 5.46%
Brazilian safrinha corn planted acreage stagnates and credit defaults increase5
Diluted EPS compresses toward the consensus low of $2.50 in FY20271
Extended crop commodity price deflation across corn and soybean futures impairs grower liquidity, leading to reduced applications of premium chemistries and down-trading to lower-trait seed hybrids. Brazilian planting acreage stalls amidst tight credit and foreign exchange drag, while generic chemical pricing pressure accelerates. Operating margins compress toward historical downcycle levels and forward earnings contract toward the lowest tier of analyst projections.
Ways this thesis can break
Severe Agrochemical Downcycle and Generic Deflation
Generic agrochemical price deflation accelerates as off-patent active ingredients flood distribution channels. Crop protection pricing declined low single digits in 1H 2026 with mid-single digit declines expected in 2H. In FY2023, consolidated operating margin collapsed to 5.46% ($941M operating income on $17,226M revenue), and direct peer FMC suffered an operating margin decline to 11.83% and net loss of -84.83%. Consolidated operating margin falling below 12.0% within 12 months generates an estimated fair value impact of -24.5%.4,5
FV impact
-8.9%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Latin American Planting Contraction and Credit Freeze
Brazil generated $2,900M and Latin America $3,928M in FY2025 revenue. Brazilian farmers face tight credit and halted safrinha acreage expansion. Historical 5-year revenue CAGR was -0.10%, and consensus FY2027 EPS has already been revised down to $3.23. Latin America regional revenue contracting by more than 2% YoY over an 18-month horizon produces an estimated fair value impact of -28.0%.1,5,7
FV impact
-11.2%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 18 months
Multiple Derating on Cyclical Peak Earnings Realization
The primary model assumes a terminal P/E of 15.5x, a substantial premium over the peer median forward P/E of 11.94x (CF at 10.41x, MOS at 13.47x, FMC at 5.23x). A derating of 20% toward peer median levels occurs as FY2027 consensus EPS contracts to $3.23. A valuation multiple contraction below 12.4x over a 24-month horizon yields an estimated fair value impact of -18.5%.1,4
FV impact
-5.5%
Terminal multiple 20% lower
Early-warning signals to monitor
The five developments that would weaken our investment case.
Indicates loss of hybrid pricing power and failure of out-licensing royalties to offset farmer down-trading to lower-trait varieties amid grain commodity deflation.
Corteva's economic profit durability is further reinforced by its counter-seasonal geographic footprint, spanning North America ($8,269M US revenue) and Latin America ($3,928M revenue, led by $2,900M in Brazil). While trailing ROIC of 7.02% currently sits close to its cost of equity of 7.9368%, it exceeds WACC of 6.4875%, and the ongoing substitution of high-margin licensing royalties for commoditized active ingredients supports expanding economic returns across the 10-year moat fade horizon.
01Proprietary Seed Germplasm and Biotech Trait Licensing Platform — The Seed segment generated $9,898M in FY2025 revenue (56.88% of consolidated sales), underpinned by proprietary Pioneer germplasm and Enlist E3 biotechnology traits. Trait licensing is tracking three years ahead of management's original multi-year plan, establishing an out-licensing platform that generates high-margin recurring royalties from third-party seed producers and eliminates external trait royalty outflows.Wide
02Patented Crop Protection Active Molecules and Formulation Switching Costs — Crop Protection generated $7,503M in FY2025 revenue. New patented molecules and biological formulations are touching $2.0B in annual revenue in FY2026 with favorable pricing execution, supported by an R&D pipeline of seven new active ingredients over the next decade. Integrated chemical-trait programs create meaningful grower switching costs against generic substitutes.Moderate
03Global Dual-Hemisphere Distribution and Route-to-Market Scale — Corteva maintains extensive direct-to-grower sales agency networks in North America ($8,269M US revenue in FY2025) paired with scaled retail distribution in Latin America ($3,928M FY2025 revenue, including $2,900M in Brazil). This dual-hemisphere route-to-market provides year-round asset utilization and distribution density that pure-play generic manufacturers cannot replicate.Moderate
Generic Agrochemical Price Deflation and Competitor Off-Patent Flooding
high
12-24 months
Aggressive portfolio rotation toward proprietary patented chemistries and biologicals touching $2.0B in FY2026, complemented by a pipeline of seven new active molecules over the next decade.5
Farmer Margin Compression and Seed Trait Downgrading
medium
12-36 months
Demonstrated multi-year yield advantages and ROI data for Pioneer hybrids and Enlist weed control systems defend pricing power and support out-licensing royalties.5
Latin American Macroeconomic and Grower Credit Distress
medium
6-18 months
Utilization of structured grain-barter contracts, credit insurance, and selective distributor financing terms in Brazil to safeguard receivables and preserve volume.5
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Corteva executes on its core operational strategy: Seed segment trait out-licensing continues tracking three years ahead of plan, offsetting broader crop price softening. Crop Protection new patented products touch $2.0B in FY2026, neutralizing mid-single-digit price declines in legacy chemistries. Latin American growth moderates to low-single-digit rates due to tight farmer credit. Cash generation remains robust, funding steady share repurchases and balance sheet health.5
Proprietary seed trait licensing expands ahead of schedule across third-party seed networks, driving substantial margin expansion. Patented crop protection molecules and biologicals exceed commercial launch targets, capturing market share from distressed commodity competitors. Brazilian safrinha corn planted area expands briskly, lifting Latin American revenue growth above historical trend and driving diluted EPS to the high end of analyst estimates.
Miss
Downgrade the rating; Pause incremental capital additions, re-evaluate operating margin durability against the twelve percent danger threshold, and review Latin American receivables.
Earnings contraction below consensus floor driven by accelerated generic pricing erosion or Brazilian credit write-offs would narrow the margin expansion trajectory, justifying a moderated stance.
Earnings quality is high, evidenced by GAAP net income of $1,094M converting into $3,406M in operating cash flow and $2,815M in free cash flow in FY2025. Depreciation and amortization of $1,203M reflects substantial tangible and intangible asset amortization post-separation. Annual stock-based compensation is modest at $54M, while cash share repurchases of $1,071M in FY2025 drove real economic share count reduction from 681.4M diluted shares.4,6
Metrics to watch into the print
01
Metric:
Seed Trait Out-Licensing Royalty Trajectory
CurrentTracking literally three years ahead of original multi-year plan
Why it matters
Core engine of gross margin expansion and out-licensing net cash inflows across corn and soybean platforms.
02
Metric:
New Patented Crop Protection Product Sales
CurrentPacing to touch $2.0B in FY2026 with favorable pricing execution
Why it matters
Crucial offset against mid-single-digit price declines in legacy chemical molecules and generic competition.
03
Metric:
Brazilian Grower Credit and Safrinha Acreage
CurrentGrower credit is tight and planted safrinha corn acreage is projected flat
Why it matters
Brazil generated $2,900M in FY2025; credit liquidity governs order placement timing and receivables risk.7
04
Metric:
Crop Protection Pricing Dynamics
CurrentLow-single-digit price declines in 1H 2026 with mid-single-digit declines expected in 2H 2026
Why it matters
Tests whether new product volume growth can overcome pricing headwinds to grow segment EBITDA dollars.
Corteva exercises disciplined capital allocation, reinvesting $591M in FY2025 capital expenditures against $1,203M in depreciation and amortization. The company maintains an underleveraged balance sheet with $1.95B in net cash ($4,875M total debt). Capital return prioritizes share repurchases ($1,071M in FY2025), which significantly exceeded stock-based compensation of $54M, driving diluted shares down from 681.4M toward 648.0M by FY2030, alongside an approved dividend of $0.72 per share.
ROIC is poised to improve as operating margins expand from 10.74% in FY2025 toward projected levels of 15.2%-16.2% by FY2030, driven by the acceleration of high-margin seed trait licensing (tracking three years ahead of plan) and growth in patented crop protection molecules touching $2.0B in FY2026, which require minimal incremental capital reinvestment.
Robust Free Cash Flow Generation Supports Capital Return and Balance Sheet Resilience
Corteva generated $3,406M in operating cash flow and $2,815M in free cash flow in FY2025, supporting $1,071M in share repurchases and an underleveraged $1.95B net cash position.
Ample organic liquidity and balance sheet strength insulate Corteva from credit tightening and enable counter-cyclical share repurchases during downcycles.
Corteva Inc. (CTVA) trades at 19.1x forward earnings against a peer median of 11.9x. Its EV/EBITDA of 12.8x compares with a peer median of 10.1x. The comparison uses 4 peers: The Mosaic Company, CF Industries Holdings Inc., Freeport-McMoRan Inc. and FMC Corporation, as of 2026-10-03.
Bear cycle
A prolonged agricultural downcycle characterized by multi-year grain price deflation, tight farmer credit in Latin America halting planted acreage growth, and ongoing generic chemical price erosion compressing consolidated operating margins toward historical trough levels of 5.46%.
Secular trends
Trend
Impact
Note
Biotechnology Seed Trait Monetization and Out-Licensing
positive
Increasing grower adoption of proprietary biotech traits and weed control systems enables Corteva to expand recurring trait licensing royalties, which are running three years ahead of baseline plan.
Regulatory Restrictions on Legacy Crop Protection Chemistries
positive
Global regulatory restrictions on older, off-patent active chemical ingredients accelerate demand for differentiated biologicals and low-toxicity patented molecules, where Corteva's new product portfolio is touching $2.0B in FY2026 with seven new actives scheduled over the next decade.
Intensive double-cropping (soybeans followed by safrinha corn) in Brazil ($2,900M FY2025 revenue) provides counter-seasonal demand and multi-year volume opportunities, despite near-term grower credit headwinds.
Positioning
Corteva is uniquely positioned at the premium end of the agricultural inputs cycle due to its dual-engine structure: Seed ($9,898M FY2025 revenue) and Crop Protection ($7,503M FY2025 revenue). While chemical peers like FMC are vulnerable to generic pricing collapse, Corteva's proprietary germplasm, accelerated trait licensing (three years ahead of plan), and strong net cash position of $1.95B provide defensive resilience and operating leverage.5,7
While Latin American credit tightness and off-patent agrochemical pricing pressure present near-term cyclical friction, Corteva's new product introductions reaching $2.0B and strong balance sheet cushion cyclical downside, justifying an aggressive accumulation stance at these depressed valuation levels.5
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Discounted forecast-period cash flows ($10.80) plus discounted terminal value ($51.02) minus signed net debt per current share (-$2.92) equals the $64.73 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
